FDG-PET Lymphoma Demonstration Project Invitational Workshop

Gary J. Kelloff, Daniel M. Sullivan, Wyndham Wilson, Bruce Cheson, Malik Juweid, George Q. Mills, Andrew D. Zelenetz, Sandra J. Horning, Wolfgang Weber, Daniel J. Sargent, Lori Dodd, Edward Korn, James Armitage, Richard Schilsky, Michaele Christian, Owen A. O'Connor, Sue Jane Wang, Ann T. Farrell, Richard Pazdur, Michael GrahamRichard L. Wahl, Steven M. Larson, Lale Kostakoglu, Margaret Daube-Witherspoon, Constantine Gastonis, Barry A. Siegel, Lalitha K. Shankar, David B. Lee, Howard R. Higley, Caroline C. Sigman, Daniel Carucci, David Timko, Louis J. deGennaro, Ellen Sigal, Anna Barker, Janet Woodcock

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The proceedings of a workshop focusing on a project to evaluate the use of fluorodeoxyglucose-positron emission tomography (FDG-PET) as a tool to measure treatment response in non-Hodgkin lymphoma (NHL) are described. Sponsored by the Leukemia & Lymphoma Society, the Foundation of the National Institutes of Health, and the National Cancer Institute, and attended by representatives of the Food and Drug Administration, the Centers for Medicare and Medicaid Services, and scientists and clinical researchers from academia and the pharmaceutical and medical imaging industries, the workshop reviewed the etiology and current standards of care for NHL and proposed the development of a clinical trial to validate FDG-PET imaging techniques as a predictive biomarker for cancer therapy response. As organized under the auspices of the Oncology Biomarker Qualification Initiative, the three federal health agencies and their private sector and nonprofit/advocacy group partners believe that FDG-PET not only demonstrates the potential to be used for the diagnosis and staging of many cancers but in particular can provide an early indication of therapeutic response that is well correlated with clinical outcomes for chemotherapy for this common form of lymphoma. The development of standardized criteria for FDG-PET imaging and establishment of procedures for transmission, storage, quality assurance, and analysis of PET images afforded by this demonstration project could streamline clinical trials of new treatments for more intractable forms of lymphoma and other cancers and, hence, accelerate new drug approvals.

Original languageEnglish (US)
Pages (from-to)330-339
Number of pages10
JournalAcademic Radiology
Volume14
Issue number3
DOIs
StatePublished - Mar 1 2007

Fingerprint

Positron-Emission Tomography
Lymphoma
Education
Non-Hodgkin's Lymphoma
Clinical Trials
Drug Approval
Centers for Medicare and Medicaid Services (U.S.)
Private Sector
National Cancer Institute (U.S.)
Neoplasm Staging
National Institutes of Health (U.S.)
Diagnostic Imaging
United States Food and Drug Administration
Therapeutics
Standard of Care
Tumor Biomarkers
Industry
Leukemia
Biomarkers
Research Personnel

Keywords

  • FDG-PET
  • chemotherapy response
  • drug development
  • imaging biomarker
  • lymphoma

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Kelloff, G. J., Sullivan, D. M., Wilson, W., Cheson, B., Juweid, M., Mills, G. Q., ... Woodcock, J. (2007). FDG-PET Lymphoma Demonstration Project Invitational Workshop. Academic Radiology, 14(3), 330-339. https://doi.org/10.1016/j.acra.2006.12.003

FDG-PET Lymphoma Demonstration Project Invitational Workshop. / Kelloff, Gary J.; Sullivan, Daniel M.; Wilson, Wyndham; Cheson, Bruce; Juweid, Malik; Mills, George Q.; Zelenetz, Andrew D.; Horning, Sandra J.; Weber, Wolfgang; Sargent, Daniel J.; Dodd, Lori; Korn, Edward; Armitage, James; Schilsky, Richard; Christian, Michaele; O'Connor, Owen A.; Wang, Sue Jane; Farrell, Ann T.; Pazdur, Richard; Graham, Michael; Wahl, Richard L.; Larson, Steven M.; Kostakoglu, Lale; Daube-Witherspoon, Margaret; Gastonis, Constantine; Siegel, Barry A.; Shankar, Lalitha K.; Lee, David B.; Higley, Howard R.; Sigman, Caroline C.; Carucci, Daniel; Timko, David; deGennaro, Louis J.; Sigal, Ellen; Barker, Anna; Woodcock, Janet.

In: Academic Radiology, Vol. 14, No. 3, 01.03.2007, p. 330-339.

Research output: Contribution to journalArticle

Kelloff, GJ, Sullivan, DM, Wilson, W, Cheson, B, Juweid, M, Mills, GQ, Zelenetz, AD, Horning, SJ, Weber, W, Sargent, DJ, Dodd, L, Korn, E, Armitage, J, Schilsky, R, Christian, M, O'Connor, OA, Wang, SJ, Farrell, AT, Pazdur, R, Graham, M, Wahl, RL, Larson, SM, Kostakoglu, L, Daube-Witherspoon, M, Gastonis, C, Siegel, BA, Shankar, LK, Lee, DB, Higley, HR, Sigman, CC, Carucci, D, Timko, D, deGennaro, LJ, Sigal, E, Barker, A & Woodcock, J 2007, 'FDG-PET Lymphoma Demonstration Project Invitational Workshop', Academic Radiology, vol. 14, no. 3, pp. 330-339. https://doi.org/10.1016/j.acra.2006.12.003
Kelloff GJ, Sullivan DM, Wilson W, Cheson B, Juweid M, Mills GQ et al. FDG-PET Lymphoma Demonstration Project Invitational Workshop. Academic Radiology. 2007 Mar 1;14(3):330-339. https://doi.org/10.1016/j.acra.2006.12.003
Kelloff, Gary J. ; Sullivan, Daniel M. ; Wilson, Wyndham ; Cheson, Bruce ; Juweid, Malik ; Mills, George Q. ; Zelenetz, Andrew D. ; Horning, Sandra J. ; Weber, Wolfgang ; Sargent, Daniel J. ; Dodd, Lori ; Korn, Edward ; Armitage, James ; Schilsky, Richard ; Christian, Michaele ; O'Connor, Owen A. ; Wang, Sue Jane ; Farrell, Ann T. ; Pazdur, Richard ; Graham, Michael ; Wahl, Richard L. ; Larson, Steven M. ; Kostakoglu, Lale ; Daube-Witherspoon, Margaret ; Gastonis, Constantine ; Siegel, Barry A. ; Shankar, Lalitha K. ; Lee, David B. ; Higley, Howard R. ; Sigman, Caroline C. ; Carucci, Daniel ; Timko, David ; deGennaro, Louis J. ; Sigal, Ellen ; Barker, Anna ; Woodcock, Janet. / FDG-PET Lymphoma Demonstration Project Invitational Workshop. In: Academic Radiology. 2007 ; Vol. 14, No. 3. pp. 330-339.
@article{3d1948bdd4d845048ec131fef80c7da1,
title = "FDG-PET Lymphoma Demonstration Project Invitational Workshop",
abstract = "The proceedings of a workshop focusing on a project to evaluate the use of fluorodeoxyglucose-positron emission tomography (FDG-PET) as a tool to measure treatment response in non-Hodgkin lymphoma (NHL) are described. Sponsored by the Leukemia & Lymphoma Society, the Foundation of the National Institutes of Health, and the National Cancer Institute, and attended by representatives of the Food and Drug Administration, the Centers for Medicare and Medicaid Services, and scientists and clinical researchers from academia and the pharmaceutical and medical imaging industries, the workshop reviewed the etiology and current standards of care for NHL and proposed the development of a clinical trial to validate FDG-PET imaging techniques as a predictive biomarker for cancer therapy response. As organized under the auspices of the Oncology Biomarker Qualification Initiative, the three federal health agencies and their private sector and nonprofit/advocacy group partners believe that FDG-PET not only demonstrates the potential to be used for the diagnosis and staging of many cancers but in particular can provide an early indication of therapeutic response that is well correlated with clinical outcomes for chemotherapy for this common form of lymphoma. The development of standardized criteria for FDG-PET imaging and establishment of procedures for transmission, storage, quality assurance, and analysis of PET images afforded by this demonstration project could streamline clinical trials of new treatments for more intractable forms of lymphoma and other cancers and, hence, accelerate new drug approvals.",
keywords = "FDG-PET, chemotherapy response, drug development, imaging biomarker, lymphoma",
author = "Kelloff, {Gary J.} and Sullivan, {Daniel M.} and Wyndham Wilson and Bruce Cheson and Malik Juweid and Mills, {George Q.} and Zelenetz, {Andrew D.} and Horning, {Sandra J.} and Wolfgang Weber and Sargent, {Daniel J.} and Lori Dodd and Edward Korn and James Armitage and Richard Schilsky and Michaele Christian and O'Connor, {Owen A.} and Wang, {Sue Jane} and Farrell, {Ann T.} and Richard Pazdur and Michael Graham and Wahl, {Richard L.} and Larson, {Steven M.} and Lale Kostakoglu and Margaret Daube-Witherspoon and Constantine Gastonis and Siegel, {Barry A.} and Shankar, {Lalitha K.} and Lee, {David B.} and Higley, {Howard R.} and Sigman, {Caroline C.} and Daniel Carucci and David Timko and deGennaro, {Louis J.} and Ellen Sigal and Anna Barker and Janet Woodcock",
year = "2007",
month = "3",
day = "1",
doi = "10.1016/j.acra.2006.12.003",
language = "English (US)",
volume = "14",
pages = "330--339",
journal = "Academic Radiology",
issn = "1076-6332",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - FDG-PET Lymphoma Demonstration Project Invitational Workshop

AU - Kelloff, Gary J.

AU - Sullivan, Daniel M.

AU - Wilson, Wyndham

AU - Cheson, Bruce

AU - Juweid, Malik

AU - Mills, George Q.

AU - Zelenetz, Andrew D.

AU - Horning, Sandra J.

AU - Weber, Wolfgang

AU - Sargent, Daniel J.

AU - Dodd, Lori

AU - Korn, Edward

AU - Armitage, James

AU - Schilsky, Richard

AU - Christian, Michaele

AU - O'Connor, Owen A.

AU - Wang, Sue Jane

AU - Farrell, Ann T.

AU - Pazdur, Richard

AU - Graham, Michael

AU - Wahl, Richard L.

AU - Larson, Steven M.

AU - Kostakoglu, Lale

AU - Daube-Witherspoon, Margaret

AU - Gastonis, Constantine

AU - Siegel, Barry A.

AU - Shankar, Lalitha K.

AU - Lee, David B.

AU - Higley, Howard R.

AU - Sigman, Caroline C.

AU - Carucci, Daniel

AU - Timko, David

AU - deGennaro, Louis J.

AU - Sigal, Ellen

AU - Barker, Anna

AU - Woodcock, Janet

PY - 2007/3/1

Y1 - 2007/3/1

N2 - The proceedings of a workshop focusing on a project to evaluate the use of fluorodeoxyglucose-positron emission tomography (FDG-PET) as a tool to measure treatment response in non-Hodgkin lymphoma (NHL) are described. Sponsored by the Leukemia & Lymphoma Society, the Foundation of the National Institutes of Health, and the National Cancer Institute, and attended by representatives of the Food and Drug Administration, the Centers for Medicare and Medicaid Services, and scientists and clinical researchers from academia and the pharmaceutical and medical imaging industries, the workshop reviewed the etiology and current standards of care for NHL and proposed the development of a clinical trial to validate FDG-PET imaging techniques as a predictive biomarker for cancer therapy response. As organized under the auspices of the Oncology Biomarker Qualification Initiative, the three federal health agencies and their private sector and nonprofit/advocacy group partners believe that FDG-PET not only demonstrates the potential to be used for the diagnosis and staging of many cancers but in particular can provide an early indication of therapeutic response that is well correlated with clinical outcomes for chemotherapy for this common form of lymphoma. The development of standardized criteria for FDG-PET imaging and establishment of procedures for transmission, storage, quality assurance, and analysis of PET images afforded by this demonstration project could streamline clinical trials of new treatments for more intractable forms of lymphoma and other cancers and, hence, accelerate new drug approvals.

AB - The proceedings of a workshop focusing on a project to evaluate the use of fluorodeoxyglucose-positron emission tomography (FDG-PET) as a tool to measure treatment response in non-Hodgkin lymphoma (NHL) are described. Sponsored by the Leukemia & Lymphoma Society, the Foundation of the National Institutes of Health, and the National Cancer Institute, and attended by representatives of the Food and Drug Administration, the Centers for Medicare and Medicaid Services, and scientists and clinical researchers from academia and the pharmaceutical and medical imaging industries, the workshop reviewed the etiology and current standards of care for NHL and proposed the development of a clinical trial to validate FDG-PET imaging techniques as a predictive biomarker for cancer therapy response. As organized under the auspices of the Oncology Biomarker Qualification Initiative, the three federal health agencies and their private sector and nonprofit/advocacy group partners believe that FDG-PET not only demonstrates the potential to be used for the diagnosis and staging of many cancers but in particular can provide an early indication of therapeutic response that is well correlated with clinical outcomes for chemotherapy for this common form of lymphoma. The development of standardized criteria for FDG-PET imaging and establishment of procedures for transmission, storage, quality assurance, and analysis of PET images afforded by this demonstration project could streamline clinical trials of new treatments for more intractable forms of lymphoma and other cancers and, hence, accelerate new drug approvals.

KW - FDG-PET

KW - chemotherapy response

KW - drug development

KW - imaging biomarker

KW - lymphoma

UR - http://www.scopus.com/inward/record.url?scp=33847249498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847249498&partnerID=8YFLogxK

U2 - 10.1016/j.acra.2006.12.003

DO - 10.1016/j.acra.2006.12.003

M3 - Article

C2 - 17307666

AN - SCOPUS:33847249498

VL - 14

SP - 330

EP - 339

JO - Academic Radiology

JF - Academic Radiology

SN - 1076-6332

IS - 3

ER -